Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 9
Mylan NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 10
Mylan NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 11
Mylan NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 12
Mylan NV, Medical Devices Deals, 2011 to YTD 2017 14
Mylan NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 15
Mylan NV, Pharmaceuticals & Healthcare, Deal Details 20
Asset Purchase 20
Mylan Acquires Global Rights to Cold-EEZE Brand from ProPhase Labs 20
Mylan Acquires Topical Pharmaceutical Business of Renaissance for up to USD1 Billion 21
Teva Pharma May Divest its Assets 22
Mylan Acquires Female Health Care Businesses from Famy Care for USD800 Million 24
Mylan Acquires Branded Generics Business of Abbott for USD5.3 Billion 26
Mylan to Acquire Rights to Arixtra Injection from Aspen Global 28
Mylan Acquires Rights To Lama Respiratory Compound From Pfizer 29
Mylan Completes Acquisition Of Drug Manufacturing Plant From Unichem For US$30 Million 30
Rottapharm|Madaus Acquires Zyma Brands 31
Meda Acquires OTC Sleep Aid Product, MidNite 32
Mylan Labs To Acquire Manufacturing Unit Of SMS Pharma For US$33 Million 33
Meda Completes Acquisition Of Women’s Health Business From Jazz Pharma For US$95 Million 34
Mylan Acquires Clindamycin Phosphate And Benzoyl Peroxide Gel From Valeant Pharma International 36
Mylan Completes Acquisition Of Respiratory Delivery Platform From Pfizer For US$348 Million 37
Meda Acquires Rights to Three Nordic OTC Drugs from McNeil and Cilag for USD111 Million 39
Meda Completes Acquisition Of Global Rights To Elidel From Novartis For US$420 Million 40
Meda Acquires Two Additional OTC Products In US From GlaxoSmithKline 42
Private Equity 43
Riverside Acquires Euromed from Meda for USD86.7 Million 43
Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 44
Partnerships 46
Mylan Enters Into Licensing Agreement With Biocon For Three Generic Insulin Products 46
Unimedic Enters into Distribution Agreement with Mylan 47
Mabion Enters into Distribution Agreement with Mylan 48
Pulmatrix Enters into Co-Development Agreement with Mylan 49
AB-Biotics Enters into Distribution Agreement with Mylan 50
Mylan Pharma Enters into Distribution Agreement with Gilead Sciences 51
Theravance Biopharma Enters into Development and Commercialization Agreement with Mylan 52
Meda Enters Promotion Agreement With Mission Pharmacal For Elestrin 53
Mylan Pharma Enters Into Distribution Agreement With Gilead Sciences 54
Venus Pharma Enters Into Co-Marketing Agreement With Mylan For Meropenem 56
Meda Expands Co-Development Agreement With Cipla For Dymista 57
Pfizer To Enter Into Co-Development Agreement With Mylan For Generic Drugs 58
Agila Specialties Forms Joint Venture With Jamp Pharma 59
Meda Enters Into Co-Marketing Agreement With Omega Pharma For SB12 60
Matrix Labs Plans Co-Marketing Agreement For 100 Products 61
Bristol-Myers Squibb Enters Into Co-Marketing Agreement With Matrix Labs 62
Licensing Agreements 63
Mylan Pharma Enters into Licensing Agreement with Otsuka Novel Products for Delamanid 63
Mylan Enters into Licensing Agreement with Genentech and Roche 64
Mylan Enters into Licensing Agreement with Medicines Patent Pool 65
Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company for Daclatasvir 66
Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 67
Mylan Ireland Enters into Licensing Agreement with Momenta Pharma 68
Gilead Sciences Expands Licensing Agreement with Mylan Labs 70
Mylan Enters into Licensing Agreement with Medicines Patent Pool for HIV Medicines 71
Mylan Enters into Licensing Agreement with MPP and ViiV Healthcare for Dolutegravir 72
Gilead Sciences Expands Licensing Agreement with Mylan Labs 73
Gilead Sciences Enters into Licensing Agreement with Mylan Labs for Tenofovir Alafenamide 74
Venus Pharma Enters into Licensing Agreement with Mylan for Meropenem 75
Prosonix Enters Into Licensing Agreement With Mylan For PSX1001 And PSX1050 76
Mylan Enters Into Licensing Agreement With Orion for Stalevo 77
Phosphagenics Enters Into Licensing Agreement With Agila Specialties For TPM Technology 78
Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 79
Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 81
Moberg Pharma Amends Licensing Agreement with Meda 82
Meda Enters Into Licensing Agreement With Moberg Derma For Nalox 83
Gilead Sciences Extends Licensing Agreement With Matrix Labs For Tenofovir, Elvitegravir, Cobicistat And Quad 84
Valeant Pharma Enters Into Licensing Agreement With Meda For Elidel And Xerese 86
Meda Amends Licensing Agreement With Medivir For Xerese 88
Tibotec Pharma Enters Into Licensing Agreement With Matrix Labs For TMC278 89
Equity Offering 91
Abbott Sells stock of Mylan for USD2.29 Billion 91
Meda to Raise USD278.7 Million in Rights Offering 92
Rottapharm Withdraws IPO for USD614.7 Million 94
Debt Offering 95
Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020 95
Mylan Raises USD796 Million in Private Placement of 1.25% Notes Due 2020 96
Mylan Raises USD796 Million in Private Placement of 3.125% Notes Due 2028 97
Mylan Raises USD531 Million in Private Placement of Floating Rate Notes Due 2018 98
Mylan Raises USD1.06 Billion in Private Placement of 2.25% Notes Due 2024 99
Mylan Raises USD1 Billion in Private Placement of 2.5% Notes Due 2019 100
Mylan Raises USD2.25 Billion in Private Placement of 3.15% Notes Due 2021 101
Mylan Raises USD2.25 Billion in Private Placement of 3.95% Notes Due 2026 102
Mylan Raises USD1 Billion in Private Placement of 5.25% Notes Due 2046 103
Mylan Raises USD500 Million in Private Placement 3.75% Notes Due 2020 104
Mylan Raises USD500 Million in Private Placement 3% Notes Due 2018 105
Mylan Completes Public Offering Of Notes Due 2043 For US$500 Million 106
Mylan Completes Public Offering Of Notes Due 2016 For US$500 Million 108
Mylan Completes Public Offering Of Notes Due 2023 For US$500 Million 110
Mylan Completes Public Offering Of Notes Due 2019 For US$500 Million 112
Mylan Completes Private Placement Of Notes Due 2018 For US$650 Million 113
Mylan Completes Private Placement Of Notes Due 2016 For US$500 Million 114
Meda Prices Public Offering Of Notes Due 2016 For US$62 Million 115
Meda Prices Public Offering Of Notes Due 2018 For US$92.4 Million 116
Mylan Completes Private Placement Of Notes Due 2023 For US$750 Million 117
Acquisition 118
Mylan Acquires Meda for USD9.9 Billion 118
Teva Pharma, Mylan May Acquire Teut|Pfizer 120
Meda Acquires Rottapharm from Fidim for USD3 Billion 122
Fidim Acquires Rottapharm Biotech from Rottapharm 123
Meda Acquires ZpearPoint, Dental Products Provider 124
Mylan Completes Acquisition Of Agila Specialties From Strides Arcolab For Up To US$1.75 Billion 125
Mylan Rumored To Acquire Bafna Pharma 128
Meda Completes Acquisition Of Acton Pharma For Up To US$200 Million 129
Mylan Acquires Synerx Pharma, Generic Maker 131
Meda Completes Acquisition Of Antula From Healthcare Brands 132
Mylan NV – Key Competitors 133
Mylan NV – Key Employees 134
Mylan NV – Locations And Subsidiaries 135
Head Office 135
Other Locations & Subsidiaries 135
Recent Developments 142
Financial Announcements 142
Nov 06, 2017: Mylan Reports Third Quarter 2017 Results and Updates 2017 Guidance 142
Aug 09, 2017: Mylan Reports Second Quarter 2017 Results and Updates 2017 Guidance 144
May 10, 2017: Mylan Reports First Quarter 2017 Results 148
Mar 01, 2017: Mylan Reports Fourth Quarter and Full Year 2016 Results and Provides 2017 Guidance 150
Nov 09, 2016: Mylan Reports Third Quarter 2016 Results 152
Aug 09, 2016: Mylan Reports Strong Second Quarter 2016 Results Including Total Revenues Up 8% 156
May 03, 2016: Mylan Reports Strong First Quarter 2016 Earnings Results Including Total Revenues Up 17% 159
Feb 10, 2016: Mylan Full Year Adjusted Diluted EPS Up 21% to $4.30 161
Corporate Communications 165
Nov 10, 2017: Mylan Announces Voluntary Delisting from the Tel Aviv Stock Exchange 165
Sep 13, 2017: Mylan Names Dennis Zeleny as Chief Human Relations Officer 166
May 01, 2017: Mylan Nominates Sjoerd Vollebregt for Election to Board of Directors 167
Mar 28, 2017: Mylan Names Former SEC Commissioner Daniel Gallagher as Chief Legal Officer 168
Dec 20, 2016: Mylan launches authorised generic version of EpiPen 169
Jun 23, 2016: Mylan Donates €1 Million to the Princess Máxima Center for Pediatric Oncology 170
May 03, 2016: Mylan Names Kenneth Parks Chief Financial Officer 171
Feb 22, 2016: Mylan Appoints Anthony Mauro Chief Commercial Officer 172
Feb 22, 2016: Mylan CEO Heather Bresch Elected Chair of Generic Pharmaceutical Association 173
Jan 08, 2016: Mylan CFO John Sheehan to Retire as of April 1, 2016 174
Legal and Regulatory 175
Nov 06, 2017: Phosphagenics Mylan Arbitration Hearing Concluded 175
Oct 31, 2017: Mylan Provides Statement in Response to Announcement of Proposed Amendments to Civil Complaint 176
Aug 25, 2016: Teva Plunges After Two U.S. Copaxone Patents Invalidated 177
Product News 179
Nov 29, 2016: New ADEKplus a Fat Soluble Nutritional Product Launched to Aid Conditions Such as Cystic Fibrosis 179
09/14/2017: Mylan Expands Womens Healthcare Portfolio with Launch of Generic Minastrin 24 FE Tablets 180
Product Approvals 181
Jan 11, 2016: Mylan Confirms FDA Submission of ANDA for Generic Advair Diskus 181
Other Significant Developments 182
Mar 08, 2016: Mylan Health Hackathon to Focus on Delivering Better Health for a Better World 182
Appendix 183
Methodology 183
About GlobalData 183
Contact Us 183
Disclaimer 183
Mylan NV, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 9
Mylan NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 10
Mylan NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 11
Mylan NV, Deals By Therapy Area, 2011 to YTD 2017 12
Mylan NV, Medical Devices Deals, 2011 to YTD 2017 14
Mylan NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 15
Mylan Acquires Global Rights to Cold-EEZE Brand from ProPhase Labs 20
Mylan Acquires Topical Pharmaceutical Business of Renaissance for up to USD1 Billion 21
Teva Pharma May Divest its Assets 22
Mylan Acquires Female Health Care Businesses from Famy Care for USD800 Million 24
Mylan Acquires Branded Generics Business of Abbott for USD5.3 Billion 26
Mylan to Acquire Rights to Arixtra Injection from Aspen Global 28
Mylan Acquires Rights To Lama Respiratory Compound From Pfizer 29
Mylan Completes Acquisition Of Drug Manufacturing Plant From Unichem For US$30 Million 30
Rottapharm|Madaus Acquires Zyma Brands 31
Meda Acquires OTC Sleep Aid Product, MidNite 32
Mylan Labs To Acquire Manufacturing Unit Of SMS Pharma For US$33 Million 33
Meda Completes Acquisition Of Women's Health Business From Jazz Pharma For US$95 Million 34
Mylan Acquires Clindamycin Phosphate And Benzoyl Peroxide Gel From Valeant Pharma International 36
Mylan Completes Acquisition Of Respiratory Delivery Platform From Pfizer For US$348 Million 37
Meda Acquires Rights to Three Nordic OTC Drugs from McNeil and Cilag for USD111 Million 39
Meda Completes Acquisition Of Global Rights To Elidel From Novartis For US$420 Million 40
Meda Acquires Two Additional OTC Products In US From GlaxoSmithKline 42
Riverside Acquires Euromed from Meda for USD86.7 Million 43
Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 44
Mylan Enters Into Licensing Agreement With Biocon For Three Generic Insulin Products 46
Unimedic Enters into Distribution Agreement with Mylan 47
Mabion Enters into Distribution Agreement with Mylan 48
Pulmatrix Enters into Co-Development Agreement with Mylan 49
AB-Biotics Enters into Distribution Agreement with Mylan 50
Mylan Pharma Enters into Distribution Agreement with Gilead Sciences 51
Theravance Biopharma Enters into Development and Commercialization Agreement with Mylan 52
Meda Enters Promotion Agreement With Mission Pharmacal For Elestrin 53
Mylan Pharma Enters Into Distribution Agreement With Gilead Sciences 54
Venus Pharma Enters Into Co-Marketing Agreement With Mylan For Meropenem 56
Meda Expands Co-Development Agreement With Cipla For Dymista 57
Pfizer To Enter Into Co-Development Agreement With Mylan For Generic Drugs 58
Agila Specialties Forms Joint Venture With Jamp Pharma 59
Meda Enters Into Co-Marketing Agreement With Omega Pharma For SB12 60
Matrix Labs Plans Co-Marketing Agreement For 100 Products 61
Bristol-Myers Squibb Enters Into Co-Marketing Agreement With Matrix Labs 62
Mylan Pharma Enters into Licensing Agreement with Otsuka Novel Products for Delamanid 63
Mylan Enters into Licensing Agreement with Genentech and Roche 64
Mylan Enters into Licensing Agreement with Medicines Patent Pool 65
Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company for Daclatasvir 66
Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 67
Mylan Ireland Enters into Licensing Agreement with Momenta Pharma 68
Gilead Sciences Expands Licensing Agreement with Mylan Labs 70
Mylan Enters into Licensing Agreement with Medicines Patent Pool for HIV Medicines 71
Mylan Enters into Licensing Agreement with MPP and ViiV Healthcare for Dolutegravir 72
Gilead Sciences Expands Licensing Agreement with Mylan Labs 73
Gilead Sciences Enters into Licensing Agreement with Mylan Labs for Tenofovir Alafenamide 74
Venus Pharma Enters into Licensing Agreement with Mylan for Meropenem 75
Prosonix Enters Into Licensing Agreement With Mylan For PSX1001 And PSX1050 76
Mylan Enters Into Licensing Agreement With Orion for Stalevo 77
Phosphagenics Enters Into Licensing Agreement With Agila Specialties For TPM Technology 78
Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 79
Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 81
Moberg Pharma Amends Licensing Agreement with Meda 82
Meda Enters Into Licensing Agreement With Moberg Derma For Nalox 83
Gilead Sciences Extends Licensing Agreement With Matrix Labs For Tenofovir, Elvitegravir, Cobicistat And Quad 84
Valeant Pharma Enters Into Licensing Agreement With Meda For Elidel And Xerese 86
Meda Amends Licensing Agreement With Medivir For Xerese 88
Tibotec Pharma Enters Into Licensing Agreement With Matrix Labs For TMC278 89
Abbott Sells stock of Mylan for USD2.29 Billion 91
Meda to Raise USD278.7 Million in Rights Offering 92
Rottapharm Withdraws IPO for USD614.7 Million 94
Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020 95
Mylan Raises USD796 Million in Private Placement of 1.25% Notes Due 2020 96
Mylan Raises USD796 Million in Private Placement of 3.125% Notes Due 2028 97
Mylan Raises USD531 Million in Private Placement of Floating Rate Notes Due 2018 98
Mylan Raises USD1.06 Billion in Private Placement of 2.25% Notes Due 2024 99
Mylan Raises USD1 Billion in Private Placement of 2.5% Notes Due 2019 100
Mylan Raises USD2.25 Billion in Private Placement of 3.15% Notes Due 2021 101
Mylan Raises USD2.25 Billion in Private Placement of 3.95% Notes Due 2026 102
Mylan Raises USD1 Billion in Private Placement of 5.25% Notes Due 2046 103
Mylan Raises USD500 Million in Private Placement 3.75% Notes Due 2020 104
Mylan Raises USD500 Million in Private Placement 3% Notes Due 2018 105
Mylan Completes Public Offering Of Notes Due 2043 For US$500 Million 106
Mylan Completes Public Offering Of Notes Due 2016 For US$500 Million 108
Mylan Completes Public Offering Of Notes Due 2023 For US$500 Million 110
Mylan Completes Public Offering Of Notes Due 2019 For US$500 Million 112
Mylan Completes Private Placement Of Notes Due 2018 For US$650 Million 113
Mylan Completes Private Placement Of Notes Due 2016 For US$500 Million 114
Meda Prices Public Offering Of Notes Due 2016 For US$62 Million 115
Meda Prices Public Offering Of Notes Due 2018 For US$92.4 Million 116
Mylan Completes Private Placement Of Notes Due 2023 For US$750 Million 117
Mylan Acquires Meda for USD9.9 Billion 118
Teva Pharma, Mylan May Acquire Teut|Pfizer 120
Meda Acquires Rottapharm from Fidim for USD3 Billion 122
Fidim Acquires Rottapharm Biotech from Rottapharm 123
Meda Acquires ZpearPoint, Dental Products Provider 124
Mylan Completes Acquisition Of Agila Specialties From Strides Arcolab For Up To US$1.75 Billion 125
Mylan Rumored To Acquire Bafna Pharma 128
Meda Completes Acquisition Of Acton Pharma For Up To US$200 Million 129
Mylan Acquires Synerx Pharma, Generic Maker 131
Meda Completes Acquisition Of Antula From Healthcare Brands 132
Mylan NV, Key Competitors 133
Mylan NV, Key Employees 134
Mylan NV, Other Locations 135
Mylan NV, Subsidiaries 136